Business · 07/06/2018
FDA Renews Pulmonary-Allergy Drugs Advisory Committee for 2 Years
The FDA has renewed the Pulmonary-Allergy Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on May 30, 2020.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →